Literature DB >> 16118769

When epigenetics kills: MLL fusion proteins in leukemia.

Robert K Slany1.   

Abstract

Chromosomal aberrations that affect the MLL (Mixed Lineage Leukemia) gene at the locus 11q23 are associated with an aggressive subtype of leukemia. These alterations create MLL fusion derivatives with an active transforming potential. This review summarizes recent advances in our knowledge about normal and malignant MLL proteins with special emphasis on epigenetic processes affected by these molecules. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16118769     DOI： 10.1002/hon.739

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


  40 in total

1.  Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.

Authors:  Pei-Yun Chang; Robert A Hom; Catherine A Musselman; Li Zhu; Alex Kuo; Or Gozani; Tatiana G Kutateladze; Michael L Cleary
Journal:  J Mol Biol       Date:  2010-05-07       Impact factor: 5.469

2.  Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Authors:  Chenxi Shen; Stephanie Y Jo; Chenzhong Liao; Jay L Hess; Zaneta Nikolovska-Coleska
Journal:  J Biol Chem       Date:  2013-09-01       Impact factor: 5.157

3.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

4.  A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.

Authors:  Dorothee Mueller; Christian Bach; Deniz Zeisig; Maria-Paz Garcia-Cuellar; Sara Monroe; Arun Sreekumar; Rong Zhou; Alexey Nesvizhskii; Arul Chinnaiyan; Jay L Hess; Robert K Slany
Journal:  Blood       Date:  2007-09-12       Impact factor: 22.113

5.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Authors:  Dmitry Borkin; Shihan He; Hongzhi Miao; Katarzyna Kempinska; Jonathan Pollock; Jennifer Chase; Trupta Purohit; Bhavna Malik; Ting Zhao; Jingya Wang; Bo Wen; Hongliang Zong; Morgan Jones; Gwenn Danet-Desnoyers; Monica L Guzman; Moshe Talpaz; Dale L Bixby; Duxin Sun; Jay L Hess; Andrew G Muntean; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Cancer Cell       Date:  2015-03-26       Impact factor: 31.743

Review 6.  Challenges and opportunities in targeting the menin-MLL interaction.

Authors:  Tomasz Cierpicki; Jolanta Grembecka
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

Review 7.  The role of HTS in drug discovery at the University of Michigan.

Authors:  Martha J Larsen; Scott D Larsen; Andrew Fribley; Jolanta Grembecka; Kristoff Homan; Anna Mapp; Andrew Haak; Zaneta Nikolovska-Coleska; Jeanne A Stuckey; Duxin Sun; David H Sherman
Journal:  Comb Chem High Throughput Screen       Date:  2014-03       Impact factor: 1.339

8.  Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Authors:  Tomasz Cierpicki; Laurie E Risner; Jolanta Grembecka; Stephen M Lukasik; Relja Popovic; Monika Omonkowska; David D Shultis; Nancy J Zeleznik-Le; John H Bushweller
Journal:  Nat Struct Mol Biol       Date:  2009-12-13       Impact factor: 15.369

9.  P-TEFb- the final frontier.

Authors:  Jiri Kohoutek
Journal:  Cell Div       Date:  2009-09-02       Impact factor: 5.130

10.  Misguided transcriptional elongation causes mixed lineage leukemia.

Authors:  Dorothee Mueller; María-Paz García-Cuéllar; Christian Bach; Sebastian Buhl; Emanuel Maethner; Robert K Slany
Journal:  PLoS Biol       Date:  2009-11-24       Impact factor: 8.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.